ΔguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine and as a live mucosal delivery system for fragment C of tetanus toxin

被引:41
作者
Anderson, RJ [1 ]
Pasetti, MF [1 ]
Sztein, MB [1 ]
Levine, MM [1 ]
Noriega, FR [1 ]
机构
[1] Univ Maryland, Ctr Vaccine Dev, Baltimore, MD 21201 USA
关键词
Shigella; tetanus toxin; live vaccine;
D O I
10.1016/S0264-410X(00)00025-6
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 [免疫学];
摘要
The Delta guaBA Shigella flexneri 2a vaccine candidate, CVD 1204, was evaluated as a delivery system for the non-toxic C-terminal of tetanus toxin (fragment C), either as a polypeptide expressed in the bacteria or as a DNA vaccine. CVD 1204 was transformed with plasmid pTETnir15 which encodes the fragment C gene (tetC) under the control of the inducible prokaryotic nir15 promoter or a DNA vaccine plasmid pcDNA3tetC which encodes tetC under the eukaryotic hCMV promoter. Guinea pigs immunised intranasally (i.n.) with either recombinant strain mounted a secretory immune response against S. flexneri 2a Lipopolysaccharide (LPS) and were protected against ocular challenge with wild-type S. flexneri 2a. Both strains were effective in eliciting a serum IgG response against fragment C in guinea pigs following i.n. immunisation. Furthermore, serum from guinea pigs immunised with CVD 1204(pTETnir15) contained tetanus toxin neutralising antibodies. These results demonstrate that this S. flexneri 2a vaccine candidate can serve as a vehicle for the delivery of foreign antigens to the systemic immune system while retaining its capacity to serve as a mucosal Shigella vaccine. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:2193 / 2202
页数:10
相关论文
共 33 条
[1]
Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin [J].
Anderson, R ;
Gao, XM ;
Papakonstantinopoulou, A ;
Roberts, M ;
Dougan, G .
INFECTION AND IMMUNITY, 1996, 64 (08) :3168-3173
[2]
Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908 [J].
Barry, EM ;
GomezDuarte, O ;
Chatfield, S ;
Rappuoli, R ;
Pizza, M ;
Losonsky, G ;
Galen, J ;
Levine, MM .
INFECTION AND IMMUNITY, 1996, 64 (10) :4172-4181
[3]
Bârzu S, 1998, INFECT IMMUN, V66, P77
[4]
IDENTIFICATION OF ICSA, A PLASMID LOCUS OF SHIGELLA-FLEXNERI THAT GOVERNS BACTERIAL INTRA-CELLULAR AND INTERCELLULAR SPREAD THROUGH INTERACTION WITH F-ACTIN [J].
BERNARDINI, ML ;
MOUNIER, J ;
DHAUTEVILLE, H ;
COQUISRONDON, M ;
SANSONETTI, PJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (10) :3867-3871
[5]
PREVENTION OF SHIGELLOSIS BY A SALMONELLA-TYPHI-SHIGELLA SONNEI BIVALENT VACCINE [J].
BLACK, RE ;
LEVINE, MM ;
CLEMENTS, ML ;
LOSONSKY, G ;
HERRINGTON, D ;
BERMAN, S ;
FORMAL, SB .
JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (06) :1260-1265
[6]
USE OF THE NIRB PROMOTER TO DIRECT THE STABLE EXPRESSION OF HETEROLOGOUS ANTIGENS IN SALMONELLA ORAL VACCINE STRAINS - DEVELOPMENT OF A SINGLE-DOSE ORAL TETANUS VACCINE [J].
CHATFIELD, SN ;
CHARLES, IG ;
MAKOFF, AJ ;
OXER, MD ;
DOUGAN, G ;
PICKARD, D ;
SLATER, D ;
FAIRWEATHER, NF .
BIO-TECHNOLOGY, 1992, 10 (08) :888-892
[7]
COFFMAN RL, 1988, MONOGR ALLERGY, V24, P96
[8]
Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults [J].
Cohen, D ;
Ashkenazi, S ;
Green, MS ;
Gdalevich, M ;
Robin, G ;
Slepon, R ;
Yavzori, M ;
Orr, N ;
Block, C ;
Ashkenazi, I ;
Shemer, J ;
Taylor, DN ;
Hale, TL ;
Sadoff, JC ;
Pavliakova, D ;
Schneerson, R ;
Robbins, JB .
LANCET, 1997, 349 (9046) :155-159
[9]
Oral somatic transgene vaccination using attenuated S-typhimurium [J].
Darji, A ;
Guzman, CA ;
Gerstel, B ;
Wachholz, P ;
Timmis, KN ;
Wehland, J ;
Chakraborty, T ;
Weiss, S .
CELL, 1997, 91 (06) :765-775
[10]
DNA vaccines [J].
Donnelly, JJ ;
Ulmer, JB ;
Shiver, JW ;
Liu, MA .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :617-648